Eli Lilly to expand production following soaring Mounjaro sales
Sales of Eli Lilly’s type 2 diabetes drug Mounjaro (tirzepatide) could have been even higher than the USD 1.4bn the drug brought in during the third quarter.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Mounjaro co-leads Eli Lilly to significant revenue growth
For subscribers
UK approval paves way for wider use of Mounjaro
For subscribers